Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, active comparator study to evaluate the antihypertensive efficacy and safety of losartan/HCTZ [hydrochlorothiazide] combination as compared to losartan monotherapy in pediatric patients with essential hypertension.

Next Previous
X
Search
Trial Profile

A randomized, double-blind, active comparator study to evaluate the antihypertensive efficacy and safety of losartan/HCTZ [hydrochlorothiazide] combination as compared to losartan monotherapy in pediatric patients with essential hypertension.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Losartan/hydrochlorothiazide (Primary) ; Losartan
  • Indications Essential hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Organon

    • Most Recent Events

    • 15 Jun 2019 This trial has been discontinued in United Kingdom, according to European Clinical Trials Database.
    • 09 Feb 2012 Planned number of patients changed from 300 to 600 as reported by ClinicalTrials.gov.
    • 03 May 2010 New source identified and integrated (United Kingdome Clinical Research Network record 3828).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top